EasySep™ Release Human Biotin Positive Selection Kit
Immunomagnetic positive selection of biotin-conjugated antibody-labeled human cells using particle release technology
Easily isolate highly purified and magnetic particle-free human cells labeled with biotinylated antibodies from fresh or previously frozen human peripheral blood mononuclear cells (PBMCs) and washed leukapheresis samples, by immunomagnetic positive selection, with the EasySep™ Release Human Biotin Positive Selection Kit. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.
In this EasySep™ positive selection procedure, desired cells are first labeled with antibody complexes recognizing biotin and magnetic particles called EasySep™ Releasable RapidSpheres™. Unlike traditional magnetic particles, which stay bound to the target cells, these RapidSpheres™ have a releasable feature. After separation using an EasySep™ magnet, bound magnetic particles are removed from the EasySep™-isolated, biotin antibody-labeled cells using a release agent, and unwanted cells are targeted for depletion. The final isolated fraction contains highly purified biotin+ cells that are immediately ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins, or other chemically related ligands.
This product replaces the EasySep™ Human Biotin Positive Selection Kit (Catalog #18553), providing highly purified particle-free cells.
Learn more about how immunomagnetic EasySep™ technology works. Explore additional products optimized for your workflow, including those for culture media, supplements, antibodies, and more.
In this EasySep™ positive selection procedure, desired cells are first labeled with antibody complexes recognizing biotin and magnetic particles called EasySep™ Releasable RapidSpheres™. Unlike traditional magnetic particles, which stay bound to the target cells, these RapidSpheres™ have a releasable feature. After separation using an EasySep™ magnet, bound magnetic particles are removed from the EasySep™-isolated, biotin antibody-labeled cells using a release agent, and unwanted cells are targeted for depletion. The final isolated fraction contains highly purified biotin+ cells that are immediately ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins, or other chemically related ligands.
This product replaces the EasySep™ Human Biotin Positive Selection Kit (Catalog #18553), providing highly purified particle-free cells.
Learn more about how immunomagnetic EasySep™ technology works. Explore additional products optimized for your workflow, including those for culture media, supplements, antibodies, and more.
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
未找到
Resources and Publications
Educational Materials (8)
Publications (1)
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer immunology research 2022 sep
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell-leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity. See related Spotlight by Zhao and Melenhorst, p. 1040.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
